Altshuler Shaham’s Acceleron Pharma XLRN Stock Holding History

Altshuler Shaham’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-51,165	Closed	-$6.42M	–	702
2021 Q2	$6.42M	Buy	+51,165	New	+$6.45M	0.05%	98
2018 Q4	–	Sell	-16,167	Closed	-$925K	–	322
2018 Q3	$925K	Sell	16,167 -16,167	-50%	-$794K	0.05%	90
2018 Q2	$1.57M	Buy	32,334 +13,000	+67%	+$474K	0.13%	67
2018 Q1	$756K	Sell	19,334 -3,066	-14%	-$130K	0.1%	85
2017 Q4	$951K	Buy	+22,400	New	+$840K	0.13%	59

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Altshuler Shaham's XLRN Position: Q3 2021 in Review

Altshuler Shaham sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 51,165 shares — an estimated $6.42M sold.

Altshuler Shaham first reported a position in XLRN in Q4 2017 and held it in 5 quarters. The position peaked at $6.42M in Q2 2021. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Altshuler Shaham reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
Altshuler Shaham sold 51,165 Acceleron Pharma shares in Q3 2021, an estimated $6.42M.
Altshuler Shaham first reported a position in Acceleron Pharma in Q4 2017 and held it in 5 quarters.
Altshuler Shaham's Acceleron Pharma position peaked at $6.42M in Q2 2021.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Altshuler Shaham's 13F filing for Q3 2021, filed 15 Nov 2021.